undamentalytics Newsletter
Sign in

China Pharma Holdings, Inc. income statement

In fiscal 2025, China Pharma Holdings, Inc. reported revenue of $4.1m, down 8.5% on the year before, operating income of −$3.2m (a -78.2% margin) and net income of −$3.2m, or −$0.74 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue74815533222016131211111087544
Cost of revenue44523923171612111099997743
Gross profit302914−031322120−0−0−2−00
Research and development——023100000000000
General and administrative34322222222221224
Operating income25226−19−39−14−8−19−10−20−3−3−4−3−5−3−4
Interest expense−0−0−0−01−111000100000
Income before tax1236−19−39−15−9−19−11−21−3−3−4−3−5−3−4
Income tax−3−3−1−1−0000−0————————
Net income23195−20−40−15−9−19−11−21−3−3−4−3−5−3−4
Diluted EPS$1.08$0.88$11.00−$0.92−$1.82−$0.70−$21.00−$44.00−$25.00−$48.00−$7.00−$74.00−$7.56−$1.82−$2.71−$0.74—
Diluted shares (average)—22m22m—22m22m22m22m22m22m22m23m—2m2m4m—
EBITDA26237−17−37−11−5−15−7−1700−10−2−2−3

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CPHI vs TXMDCPHI vs EYPTCPHI vs NTRB

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China Pharma Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to China Pharma Holdings, Inc.